EUCTR2013-001473-24-AT进行中（未招募）不适用
An Individualized treatMent aPproach for oldER patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus - IMPERIUM
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 880
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The study will include patients who are:
- •Patients with T2DM based on a history and clinical impression that is consistent with the World Health Organization [WHO] Classification of Diabetes
- •Male or female
- •Are at least 65 years of age at the time of screening
- •Have a CFS of 4 or above AND/OR TIBI score of 5 or above as assessed at Visit 1
- •Have an A1c >7.3% and <10.9% at study entry and are not achieving desired glycemic control as evidenced by A1c measurement at least 0.4% higher than individualized treatment target set at Visit 1.
- •Have been treated for at least 3 months prior to the study entry with any of the following treatment options:
- •odiet/exercise only (only if they have known contraindications to metformin treatment)
- •oany dose of sulfonylurea
- •oeffective or maximally tolerated doses of metformin, dipeptidyl-peptidase-4 (DPP-4) inhibitor, thiazolidinedione, or acarbose used in monotherapy or in dual combination. The following doses are considered to be effective:
- •?at least 1500 mg of metformin per day
- •?at least 30 mg of pioglitazone per day
- •?at least 4 mg of rosiglitazone per day
- •?at least 75 mg of acarbose per day
- •?any marketed dose of DPP-4 inhibitor
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 970
排除标准
- •Patients will be excluded from the study based on the following criteria:
- •Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted
- •Are Lilly employees or are employees of third-party organizations (TPOs) involved in study who require exclusion of their employees
- •Are currently enrolled in a clinical trial involving an investigational product or nonapproved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- •Have participated, within the last 60 days in a clinical trial involving an investigational product other than the investigational product used in this study. If the previous investigational product has a long half life, 3 months or 5 half-lives (whichever is longer) should have passed
- •Have previously completed or withdrawn from this study. This exclusion criterion does not apply to patients who are rescreened prior to randomization.
- •At study entry have contraindications to sulfonylurea, insulin, or GLP-1 RA
- •Have a history of pancreatitis, a personal or family history of medullary thyroid carcinoma, or have Multiple Endocrine Neoplasia syndrome type 2
- •Have taken any injectable glucose-lowering agent, miglitol, meglitinide, Sodium/Glucose cotransporter-2 inhibitor, or other antihyperglycemia treatment that is not listed in inclusion criterion [6] (main protocol) for more than 10 days within 3 months prior to the study entry
- •In the opinion of investigator should have an individualized A1c target set at 8% or higher
- •Have a BMI greater than 45 kg/m2
- •Have had more than 1 episode of severe hypoglycemia within 24 weeks prior to the study
- •Have cardiac disease with functional status that is Class III or IV according to the New York Heart Association Cardiac Disease Classification
- •Have an eGFR<30 mL/min/1.73 m2 or advanced renal disease including history of renal transplantation or currently receiving renal dialysis
- •Have obvious clinical signs or symptoms or laboratory evidence of liver disease (alanine aminotransferase or aspartate aminotransferase > 2.5 times the upper limit of the reference range)
- •Receive current therapy for a malignancy, other than basal-cell or squamous-cell skin cancer
- •Received systemic glucocorticoids within the 3 months prior to entry for more than 14 consecutive days.
- •Have any other condition that precludes the patient from following and completing the protocol.
研究者
相似试验
进行中（未招募）
不适用
An Individualized treatMent aPproach for oldER patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus - IMPERIUMMedDRA version: 16.1Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2013-001473-24-DEEli Lilly and Company880
进行中（未招募）
1 期
An Individualized treatMent aPproach for oldER patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus - IMPERIUMDiabetes Mellitus, Type 2EUCTR2013-001473-24-GBEli Lilly and Company880
已完成
不适用
Tailored treatment in Older Patients TOP-1: Omission of radiotherapy in elderly patients with low risk breast cancerbreast cancerNL-OMON53002eids Universitair Medisch Centrum1,200
进行中（未招募）
不适用
''Geriatric assessment adapted'' therapy for the treatment of Ph-negative Acute lymphoblastic Leukemia in elder patients. - GIMEMA LAL 1104Acute lymphoblastic leukemia Ph- of the elderMedDRA version: 14.1Level: PTClassification code 10000846Term: Acute lymphocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-002156-17-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
终止
4 期
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)Diabetes Mellitus, Type 2NCT02072096Eli Lilly and Company192